FLT3
Gene Ontology Biological Process
- B cell differentiation [ISS]
- cellular response to cytokine stimulus [ISS, TAS]
- common myeloid progenitor cell proliferation [ISS]
- cytokine-mediated signaling pathway [ISS]
- dendritic cell differentiation [ISS]
- hemopoiesis [IDA]
- leukocyte homeostasis [ISS]
- lymphocyte proliferation [ISS]
- myeloid progenitor cell differentiation [ISS]
- peptidyl-tyrosine phosphorylation [TAS]
- positive regulation of MAP kinase activity [TAS]
- positive regulation of MAPK cascade [TAS]
- positive regulation of cell proliferation [TAS]
- positive regulation of phosphatidylinositol 3-kinase activity [TAS]
- positive regulation of phosphatidylinositol 3-kinase signaling [TAS]
- positive regulation of tyrosine phosphorylation of STAT protein [TAS]
- pro-B cell differentiation [ISS]
- protein autophosphorylation [TAS]
- regulation of apoptotic process [TAS]
- transmembrane receptor protein tyrosine kinase signaling pathway [TAS]
- vascular endothelial growth factor signaling pathway [TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
PPAN
Gene Ontology Biological Process
Gene Ontology Molecular Function
Positive Genetic
Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a less severe fitness defect than expected under a given condition. This term is reserved for high or low throughput studies with scores.
Publication
A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.
Acute myeloid leukemia (AML) is a malignant hematopoietic disease and the most common type of acute leukemia in adults. The mechanisms underlying drug resistance in AML are poorly understood. Activating mutations in FMS-like tyrosine kinase 3 (FLT3) are the most common molecular abnormality in AML. Quizartinib (AC220) is a potent and selective second-generation inhibitor of FLT3. It is in clinical ... [more]
Throughput
- Low Throughput
Ontology Terms
- phenotype: growth abnormality (HP:0001507)
- phenotype: viability (PATO:0000169)
Additional Notes
- CRISPR GI screen
- Cell Line: MV4-11 cells
- Experimental Setup:Drug Exposure, 3 nM AC220
- GIST: A-phenotypic positive genetic interaction
- Library: GECKO
- Significance Threshold: Only screen hits were published
Related interactions
| Interaction | Experimental Evidence Code | Dataset | Throughput | Score | Curated By | Notes |
|---|---|---|---|---|---|---|
| FLT3 PPAN | Proximity Label-MS Proximity Label-MS An interaction is inferred when a bait-enzyme fusion protein selectively modifies a vicinal protein with a diffusible reactive product, followed by affinity capture of the modified protein and identification by mass spectrometric methods. | High | 0.01 | BioGRID | 3510510 |
Curated By
- BioGRID